MESENCHYMAL STEM-CELLS IN IN BONE-DEVELOPMENT, BONE REPAIR, AND SKELETAL REGENERATION THERAPY

被引:678
作者
BRUDER, SP
FINK, DJ
CAPLAN, AI
机构
[1] CASE WESTERN RESERVE UNIV,DEPT ORTHOPAED,CLEVELAND,OH 44106
[2] CASE WESTERN RESERVE UNIV,SKELETAL RES CTR,DEPT BIOL,CLEVELAND,OH 44106
关键词
DIFFERENTIATION; LINEAGE; OSTEOGENESIS; CHONDROGENESIS; BONE MARROW; OSTEOPOROSIS; FRACTURE REPAIR; BIOACTIVE FACTORS; MONOCLONAL ANTIBODIES;
D O I
10.1002/jcb.240560303
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Bone formation in the embryo, and during adult fracture repair and remodeling, involves the progeny of a small number of cells called mesenchymal stem cells (MSCs). These cells continuously replicate themselves, while a portion become committed to mesenchymal cell lineages such as bone, cartilage, tendon, ligament, and muscle. The differentiation of these cells, within each lineage, is a complex multistep pathway involving discrete cellular transitions much like that which occurs during hematopoiesis. Progression from one stage to the next depends on the presence of specific bioactive factors, nutrients, and other environmental cues whose exquisitely controlled contributions orchestrate the entire differentiation phenomenon. An understanding of the cellular and molecular events of osteogenic differentiation of MSCs provides the foundation for the emergence of a new therapeutic technology for cell therapy. The isolation and in vitro mitotic expansion of autologous human MSCs will support the development of novel protocols for the treatment of many clinically challenging conditions. For example, local bone defects can be repaired through site-directed delivery of MSCs in an appropriate carrier vehicle. Generalized conditions, such as osteoporosis, may be treatable by systemic administration of culture-expanded autologous MSCs or through biopharmaceutical regimens based on the discovery of critical regulatory molecules in the differentiation process. With this in mind, we can begin to explore therapeutic options that have never before been available. (C) 1994 Wiley-Liss, Inc.
引用
收藏
页码:283 / 294
页数:12
相关论文
共 53 条
[1]  
ASHHURST DE, 1991, BONE, V5, P61
[2]  
BRIGHTON CT, 1984, AAOS INT COURSE LECT, V33, P60
[3]   OSTEOCHONDRAL DIFFERENTIATION AND THE EMERGENCE OF STAGE-SPECIFIC OSTEOGENIC CELL-SURFACE MOLECULES BY BONE-MARROW CELLS IN DIFFUSION-CHAMBERS [J].
BRUDER, SP ;
GAZIT, D ;
PASSIEVEN, L ;
BAB, I ;
CAPLAN, AI .
BONE AND MINERAL, 1990, 11 (02) :141-151
[4]   OSTEOGENIC CELL LINEAGE ANALYSIS IS FACILITATED BY ORGAN-CULTURES OF EMBRYONIC CHICK PERIOSTEUM [J].
BRUDER, SP ;
CAPLAN, AI .
DEVELOPMENTAL BIOLOGY, 1990, 141 (02) :319-329
[5]   TERMINAL DIFFERENTIATION OF OSTEOGENIC CELLS IN THE EMBRYONIC CHICK TIBIA IS REVEALED BY A MONOCLONAL-ANTIBODY AGAINST OSTEOCYTES [J].
BRUDER, SP ;
CAPLAN, AI .
BONE, 1990, 11 (03) :189-198
[6]   A MONOCLONAL-ANTIBODY AGAINST THE SURFACE OF OSTEOBLASTS RECOGNIZES ALKALINE-PHOSPHATASE ISOENZYMES IN BONE, LIVER, KIDNEY, AND INTESTINE [J].
BRUDER, SP ;
CAPLAN, AI .
BONE, 1990, 11 (02) :133-139
[7]   1ST BONE-FORMATION AND THE DISSECTION OF AN OSTEOGENIC LINEAGE IN THE EMBRYONIC CHICK TIBIA IS REVEALED BY MONOCLONAL-ANTIBODIES AGAINST OSTEOBLASTS [J].
BRUDER, SP ;
CAPLAN, AI .
BONE, 1989, 10 (05) :359-375
[8]  
BUCK BE, 1989, CLIN ORTHOP RELAT R, V240, P129
[9]  
Caplan A.I., 1987, BONE MINER RES, V5th, P117
[10]   MESENCHYMAL STEM-CELLS [J].
CAPLAN, AI .
JOURNAL OF ORTHOPAEDIC RESEARCH, 1991, 9 (05) :641-650